Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Looks Into Social Media Marketing of Drugs


Pharmaceutical Marketing

According to draft guidance released in 2014, the FDA currently requires pharmaceutical marketers to present balanced risk/benefit information in the same post.

Share this!

November 11, 2016 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) requires pharmaceutical marketers to mention both the benefits and the risks of a given drug in direct-to-consumer advertisements and other types of promotion. But in the case of social media, pharmaceutical companies face tight character limitations which could prevent them fulfilling this requirement.

Now, the FDA is thinking about allowing drugmakers to provide a link to the drug’s risks in their posts. In order to test whether this strategy would be effective at communicating risk/benefit information to consumers, the regulatory agency plans to test the approach in four different studies.

The purpose of these studies will be to determine how well participants retain risk information for a fictitious prescription drug, after seeing it presented in two different formats. Two studies will show the risk information in a Google-sponsored link, and two will present the same information on Twitter, which has a 140-character limit.

The FDA has already speculated about the results of these studies. They believe that participants who view a tweet containing risk information will show greater retention, compared to the group presented with the Google-sponsored link.

While social media platforms like Twitter are seeing increased interest from pharmaceutical companies, few currently use their accounts for product promotion. Depending on the outcome of the FDA’s marketing studies, drugmarkers could see improved guidance on social media promotion, potentially allowing them to make better use of the tool.

According to draft guidance released in 2014, the FDA currently requires pharmaceutical marketers to present balanced risk/benefit information in the same post. They are also required to provide direct access to exhaustive safety information for the prescription drug.

Keywords: FDA, Direct-To-Consumer Advertising, Pharmaceutical Marketing


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.